Search Results

Nexalin Technology, Inc. (the “Company” or “Nexalin”) (Nasdaq: NXL; NXLIW) announced today that it will be participating in the Spring MicroCap Rodeo Conference, that will be held on Thursday, June 6, 2024 in New York City.

June 4, 2024

·

3 min read

Policy

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

Nexalin Technology, Inc. announced that its second generation, 15 milliamp neurostimulation device has been granted regulatory approval by the Brazilian Health Regulatory Agency, a regulatory body of the Brazilian government responsible for approving new drugs and medical devices.

June 13, 2024

·

3 min read

Press Releases

Nexalin Appointed as Industry Co-Chair of National TBI Registry Coalition

February 10, 2025

·

3 min read

Press Releases

Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements

November 4, 2024

·

2 min read

Lone Star Bio

Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23

Nexalin Technology, Inc. is pleased to invite investors to a webinar on May 23, 2024, at 4:15 p.m. ET.

May 9, 2024

·

2 min read

Lone Star Bio

Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal

Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today announced positive results of a clinical study designed to evaluate the feasibility, safety, and efficacy of transcranial alternating current dynamic frequency stimulation (tACS) as an add-on treatment for the symptoms of major depressive disorder (MDD), also known as clinical depression, a mental health condition that affects mood, behavior, appetite, and sleep.

June 26, 2024

·

6 min read